A Study Evaluating the Safety, Efficacy and Pharmacokinetics of Venetoclax in Combination With Polatuzumab Vedotin Plus Rituximab (R) and Cyclophosphamide, Doxorubicin, Prednisone (CHP) in Participants With Untreated BCL-2 Immunohistochemistry (IHC)-Positive Diffuse Large B-Cell Lymphoma (DLBCL)
Clinical trial NCT04790903 · TERMINATED
Trial details
- NCT number
- NCT04790903
- Sponsor
- Hoffmann-La Roche
- Status
- TERMINATED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2021-07-02
- Primary completion
- 2024-05-21
- Enrollment
- 50
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.